Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

• Published in: Journal of clinical medicine 2019-09, Vol.8 (9), p.1394
• Main Authors: Fautrel, Bruno, Kirkham, Bruce, Pope, Janet E, Takeuchi, Tsutomu, Gaich, Carol, Quebe, Amanda, Zhu, Baojin, de la Torre, Inmaculada, De Leonardis, Francesco, Taylor, Peter C
• Format: Article
• Language: English
• Subjects: Human health and pathology; Immunology; Immunotherapy; Life Sciences; Rhumatology and musculoskeletal system
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm8091394

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks' treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients ( = 1010) were categorised as in remission, in remission or low disease activity, or not in remission or low disease activity at week 24. For patients in remission or low disease activity ( = 310), improvements in mean pain and physical function scores at week 24 were significantly greater with baricitinib than placebo ( < 0.001 and < 0.01, respectively) and adalimumab ( < 0.05 for both). For both outcomes, differences between adalimumab and placebo were not significant. The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation.